Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
3-71 is M1 only
It is mixed 1-4
Preferred shares are much more than dilution. I hope some of you sold to buy back lower. Missling is not a liar, and I don't agree with some of his/boards decisions. This created a nice buying opportunity, depending on how the prefered shares play out. The share price should appreciate closer to readout, and we'll see how the value changes afterward.
I would say, know what the market will do to make a buck, and make one with them.
Make Money Longs!
You're not alone.
Yes, diluting at low prices is always smart, and in the best interest of shareholders.
Too late... who makes that decision?
Can be, or are? Two different things. They were passed, so what are they?
Blank check. Ask the board what they intend to do. Otherwise your guess is as good as anyone elses...
Frankly, if it was such a "good" thing, why did the share price drop? I believe it will go lower too. Been targeting 2.60, now I think it will go lower than that. Why hold a stock if you think the share price is going to go lower? I've thought this stock has been undervalued for a long time. I also believe this stock has a good chance of being very lucrative. I've been here for several years and realize it doesn't matter what I think, but to make money and hold your share you have to trade or you will be diluted from discounted sales to others. I asked IR if they had any reason to believe there would be a hostile takeover attempt. Guess what the answer was... I think Anavex 2-73 will be successful, but I wont buy your shares for $400/share I'd be glad to sell you mine now for $400/share, because it's possible it could get there.
Nice conjecture, kind of like passing the prefered shares. 20%
Not trashing the stock, just the unjustified decision to pass the preferred. Just like others on this board, I believe the science is worth the investment. I'm just trying to hold on to my share and make some money on these swings. I sold several thousand shares on this deal and only have 50k now. I may buy back later if the price drops some more.
I'm looking for a 20% discount now.
No, there is no information to share. At least we can look for a 20% discount on the stock now. Woohoo great resolution.
Well, I certainly hope your right. With all the speculation throughout the years, it would be good to have a win.
George,I wouldn't exactly call today's price action a squeeze.
That's interesting, I was thinking definitely down, sideways or up.
Hanging out close to $2.60 still... I'm targeting $2.57. We'll see if it gets there.
You know where my target is...
You too, I hope we all win!
Interesting, I think we are going under $3.
I'm still targetting a quick dip to around $2.58. May not happen, but I'm good with my position if it pops.
Thanks VG. I don't think they have ill intent either. I'm anxious for more news and hope for successful trials on all counts, not only for my pocket book, but for the many people that suffer from these neurological dissorders.
Good luck to you as well.
2.55 is a good mark.
I think the news is great, don't get me wrong, advancement has been long awaited. Trials are started, yay... finally.
Speculation of science and speculation of the boards intentions are the same in relation to an investment. Either can make you sink or swim.
The timing is a little odd, even with PR. Look at this shiny new car, payments are only $X per month... you can see loan details if you look at this other paperwork, but, it even comes in red. Did I mention how shiny it is.
Send out several PR's along with, by the way were asking for a blank check. Some people will say that they feel good about what the company is doing, why not. What could it hurt. Yeah, we don't have details about how they will be used, but look they have 3 trials started. They are doing great.
I trust the board because they did not meet any of the deadlines they communicated and will be rewarded handsomely when they are finally met. No reasons or excuses. Hey, the trials are started now.
I have no fear or doubt, only information that is provided to me.
He is also on the BOD...
How would this work... I must be missing something. If the shares are issued to stockholders the entity that is buying all the shares would also have thier position increased. I would also expect the value of the company to remain the same, in effect creating some version of a stock split. The plan would have to be time dependent AND in relation to an investors current position. Ie. The shares would be issued to stockholders that still have a position as of x date.
I would vote NO. This is in no way in the interest of current stockholders. It is in the interest of the board. If a poison pill is already in place, why issue these prefered? There is nothing in this proposal (in writing) that would benefit current stockholders and in fact it outlines ways which it would be disadvantageous to current stockholders (black and white).
Like the trials currently underway?
Why not simply cover at such low prices? There is no reason to protect thier investment. If it goes to zero there is not much more for a short to gain from $10.
If so eager to sell why not sell at the 1.51 bid sitting there?
Who is buying?
My opinion about AVXL SP drop is risk mitigation. This is a speculative play and the general market is facing a possible correction. People are looking for "safer" investments vs speculative plays. Market generalizations have been turned upside down in the past years and "safe" investments: bonds, precious metals, etc. don't perform like they have in the past and corporate giants have fallen on a whim.
They already had it in the pipeline and preclinical trials completed before 3-71 came into the picture.
Really?... Do you even remember patient enrollment? Dec 16, 2014 first patient enrolled / Sep 28, 2015 last patient enrolled.
Oh gee, next argument is that it will take over 10 years at that rate; ridiculous.
I'm fairly certain that Donepezil is no longer part of the equation. In more generic terms of MOA, mixed muscarinic receptor ligand may have similar partial effect of Donepezil, but not the same.
https://www.ncbi.nlm.nih.gov/m/pubmed/19363262/
Fizzle, fizzle...Donepezil can't hang. Are there any findings about inflamation with dosing of A2-73?
Your statement is a little generic, care to enlighten? Specifically in regard to the already tried cholinomimetics.
Thanks Doc, only this level of detail is reassuring to some, and I don't blame them. I usually don't have time anymore to pull sources or links for sharing. Someone like you sharing your intimate experience is better any day.
This is the conundrum for many. If you expect this will be "dead" money for so long, why invest now? You could certainly expect greater returns than "dead" money over however long it is expected to be "dead". Yay, PD and Rhetts. May this drug continue to show great results as in previous trials. BTW, I would still like to see an advancement in epilepsy, but I know that wont get us to market as quick as current path.
This is an interesting take to me. If the data was so cut and dry, why didn't anyone say so earlier. When the trials first started the outcome was so encouraging, or so it seemed to many. Nearly all patients seemed to benefit early on. Slowly over time there started to be a spread in patient response and the Anavex-PLUS idea fell to the way side, something else was going on. Still quite a few patients were responding, but some were more than others. This spread grew more as time went on. While discouraging to some, not all the information is available. If we conducted a larger trial and got the same results and could not explain the difference, do you think the drug would be approved? In my opinion, while encouraging, I would think that that type of outcome would have warranted yet another trial. We need THIS trial to give us the approval, otherwise expect more dilution. That is what the precision approach is supposed to provide, insight into the distinguishing factors that resulted in the difference of response. We can tackle any other slight opportunities later, but this trial needs the best shot that it can get if you are interested in growing this company without selling short to BP or massive dillution.